AbbVie's blockbuster drug is Humira, where last quarter it drove 54.5% of the company's total revenue. While it has patent protection until 2023 here in the United States, the drug lost patent protection in Europe. Imbruvica was the company's second-largest revenue generator last quarter, at $1.23 billion or just 14.3% of total revenue.